Impact of VEGF Gene Polymorphisms in Elderly Cancer Patients: Clinical Outcome and Toxicity
- 6 January 2015
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 16 (1) , 61-78
Abstract
Vascular endothelial growth factors (VEGFs) are the key regulators in angiogenesis and have been shown to play a significant role in the progression and prognosis of angiogenesis-related diseases, such as cancer. VEGF inhibitors are a current pharmacological tumoral strategy. However, despite the strong association between aging and cancer incidence and progression, recent findings suggest impaired angiogenesis accompanied by a reduced expression of VEGF in cells derived from aging subjects. Specific variations of VEGF genes have been demonstrated to be genetic determinants for susceptibility, outcome and therapy response, especially for the solid tumors. Considering the complications present in frail elderly patients, analysis of VEGF genetic polymorphisms in these subjects may further help in tailoring an angiogenic pharmacological strategy, and in improving our ability to better understand prognosis during therapy-related to cancer.Keywords
This publication has 121 references indexed in Scilit:
- Brain homeostasis: VEGF receptor 1 and 2—two unequal brothers in mindCellular and Molecular Life Sciences, 2013
- Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)Journal of Thoracic Oncology, 2012
- Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesJournal of Cancer Research and Clinical Oncology, 2009
- Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized TrialJNCI: Journal of the National Cancer Institute, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancerAnnals of Oncology, 2008
- Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literatureBritish Journal of Cancer, 2006
- Molecular regulation of vessel maturationNature Medicine, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990